Journal Article

DKFZ-2023-01083

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Outcome of Immunotherapy in Adrenocortical Carcinoma - A retrospective cohort study.

Remde, H. ; Schmidt-Pennington, L. ; Reuter, M. ; Landwehr, L.-S. ; Jensen, M. ; Lahner, H. ; Kimpel, O. ; Altieri, B. ; Laubner, K. ; Schreiner, J. ; Bojunga, J. ; Kircher, S. ; Kunze, C. A. ; Pohrt, A. ; Teleanu, M.-V.DKFZ* ; Hübschmann, D.DKFZ* ; Stenzinger, A. ; Glimm, H.DKFZ* ; Fröhling, S.DKFZ* ; Fassnacht, M. ; Mai, K. ; Kroiss, M.

2023
BioScientifica Ltd. Bristol

This record in other databases:  

Please use a persistent id in citations: doi:10.1093/ejendo/lvad054

Abstract: Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting.Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at six German reference centres between 2016 and 2022.Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAE) were assessed.In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5% (6-26) and DCR 24% (16-41). PFS was 3.0 months (95%CI 2.3-3.7). In all patients, median OS was 10.4 months (3.8-17). 17 TRAE occurred in 15 patients, which was associated with a longer PFS of 5.5 (1.9-9.2) vs. 2.5 (2.0- 3.0) months (HR 0.29, 95%CI 0.13-0.66, p=0.001) and OS of 28.2 (9.5-46.8) vs. 7.0 (4.1-10.2) months (HR 0.34, 95%CI 0.12-0.93). Positive tissue staining for programmed cell death ligand 1 (PD-L1) was associated with a longer PFS of 3.2 (2.6-3.8) vs. 2.3 (1.6-3.0, p<0.05) months. Adjusted for concomitant mitotane use, treatment with nivolumab was associated with lower risk of progression (HR 0.36, 0.15-0.90) and death (HR 0.20, 0.06-0.72) compared to pembrolizumab.In the real-life setting we observe a response comparable to other second-line therapies and an acceptable safety profile in ACC patients receiving different ICI. The relevance of PD-L1 as a marker of response and the potentially more favourable outcome in nivolumab treated patients require confirmation.

Keyword(s): PD-L1 ; adverse drug reaction ; immune checkpoint inhibitor ; mitotane ; treatment

Note: 2023 Jun 7;188(6):485-493

---

Contributing Institute(s):

1. Translationale Medizinische Onkologie (B340)
2. DKTK HD zentral (HD01)
3. B280 Translationale funktionelle Krebsgenomik (B280)
4. DKTK DD zentral (DD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2023

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---